Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 12523.155 | 0.9829 | 0.9677 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 12523.155 | 0.9720 | 0.9471 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 12523.155 | 1.0050 | 1.0095 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 12523.155 | 0.9732 | 0.9493 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 12523.155 | 0.9844 | 0.9705 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 12523.155 | 0.9944 | 0.9894 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 12523.155 | 0.9161 | 0.8410 | 1.0583 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 12523.155 | 0.9753 | 0.9532 | 1.0583 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 12239.155 | 0.9398 | 0.9430 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 12239.155 | 0.9822 | 0.9833 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 12239.155 | 1.0158 | 1.0146 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 12239.155 | 1.0068 | 1.0064 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 12239.155 | 0.9129 | 0.9169 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 12239.155 | 0.9158 | 0.9197 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 12239.155 | 0.7828 | 0.7844 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 12239.155 | 0.7866 | 0.7885 | 2.1474 | |
| HCC1806 | TNBC | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 12239.155 | 0.7952 | 0.7975 | 2.1474 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 11849.155 | 1.0089 | 1.0118 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 11849.155 | 1.0023 | 1.0031 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 11849.155 | 1.0016 | 1.0022 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 11849.155 | 1.0174 | 1.0232 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 11849.155 | 0.8959 | 0.8585 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 11849.155 | 0.9469 | 0.9285 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 11849.155 | 0.8490 | 0.7929 | 1.4975 | |
| HCC1937 | TNBC | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 11849.155 | 0.8816 | 0.8385 | 1.4975 |